Surrozen, Inc./DE — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Surrozen, Inc./DE filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.48M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $10.66M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($242.03M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($63.56M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($43.04M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($36.00M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($54.65M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($2.12M) | May 14, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($42.09M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($25.54M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($45.78M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($44.34M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($54.39M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($438.8K) | May 14, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.37M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $21.13M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $27.23M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $37.01M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $40.18M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $25.68M | Mar 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.24M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($17.63M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($40.36M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($44.15M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($48.81M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($934.0K) | May 14, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.0K | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $26.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $398.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $728.0K | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $1.27M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $874.0K | Mar 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.73M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $48.47M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $46.08M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $89.44M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $137.17M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $62.06M | Mar 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $286.49M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $69.85M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $8.15M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.43M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $27.47M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $14.77M | Mar 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($187.76M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($21.38M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | $37.94M | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | $76.00M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $109.70M | Apr 10, 2024 |
| FY2022 | Dec 31, 2020 | $47.29M | Mar 31, 2023 |
| FY2020 | Aug 20, 2020 | $0 | May 14, 2021 |
| FY2021 | Dec 31, 2019 | $29.39M | Mar 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($527.29M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($285.26M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($221.70M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($178.65M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($142.65M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($88.00M) | Mar 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.25M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $34.57M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $36.04M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $24.69M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $33.09M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $34.98M | Mar 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (32) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (21) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (21) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (32) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (21) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (21) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.78M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 3.26M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 2.06M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 2.01M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | 35.03M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 18.26M | Mar 28, 2022 |